Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) declared a third-quarter 2026 cash dividend of $1.34 per share on its common stock.
The dividend is payable on September 8, 2026 to shareholders of record and with an ex-dividend date of August 25, 2026.
Johnson & Johnson (NYSE: JNJ) reported Q2 2026 sales of $25.3 billion, up 6.6% year over year, with operational growth of 5.6% and adjusted operational growth of 5.7%. Net earnings were $5.53 billion and diluted EPS was $2.27, both slightly below prior year, while adjusted EPS rose to $2.90, up 4.7%.
Innovative Medicine sales reached $16.38 billion (7.8% reported growth) and MedTech $8.93 billion (4.5% reported growth). Free cash flow year‑to‑date was about $8.7 billion versus $6.21 billion in 2025. The company raised 2026 guidance to estimated reported sales of $100.8–$101.4 billion (7.0–7.6% growth; $101.1 billion midpoint) and adjusted EPS of $11.60–$11.75 (8.2% midpoint growth).
According to Johnson & Johnson, growth was driven by key oncology, immunology and neuroscience products, partially offset by STELARA and other legacy brands. The quarter also included multiple FDA and CE approvals, positive clinical data across several late‑stage assets, and agreements to acquire Firefly Bio and other technologies.
Johnson & Johnson (NYSE: JNJ) received U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform, a catheter ablation solution delivering both radiofrequency and pulsed field energy through a single catheter.
Integrated with the CARTO ecosystem, U.S. procedures are expected to begin this summer via a phased commercial rollout.
Johnson & Johnson (NYSE: JNJ) reported new Phase 3 Vivacity-MG3 analyses of IMAAVY (nipocalimab) in antibody-positive generalized myasthenia gravis (gMG) at EAN 2026.
Data show greater MG-ADL improvements vs placebo in early-diagnosed and lower-symptom patients, maintained control after common infections, a safety profile with 84% AEs and fewer SAEs vs placebo, and launch of the PETUNIA pregnancy outcomes study.
Johnson & Johnson (NYSE: JNJ) will invest more than $1 billion to expand its U.S. Vision manufacturing, packaging, and distribution operations in Jacksonville, Florida.
The project includes a new state-of-the-art distribution facility, targets full operation in 2028, supports 3,500 employees, and contributes to a $6 billion annual economic impact in Florida.
Johnson & Johnson (NYSE:JNJ) reported positive Phase 3 MonumenTAL-3 results for TALVEY® plus DARZALEX FASPRO® with or without pomalidomide in relapsed/refractory multiple myeloma.
The combinations cut risk of progression or death by up to 72%, showed 24‑month PFS up to 81.3% and OS up to 89.2%, with safety profiles consistent with monotherapies. Johnson & Johnson has submitted an sBLA to the FDA and a Type II variation to the EMA.
Johnson & Johnson (NYSE: JNJ) is expanding U.S. availability of its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract surgery. The lens addresses cataract-related vision loss and presbyopia in one procedure and is the first and only U.S. FDA‑approved EDOF IOL without a contrast sensitivity loss warning.
According to Johnson & Johnson, more than 500,000 eyes worldwide have received TECNIS PureSee IOL, 97% of patients would recommend it, and 97% reported no very bothersome visual disturbances. A new patient lifestyle quiz supports pre-surgery decision-making during Cataract Awareness Month.
Johnson & Johnson (NYSE: JNJ) reported pivotal Phase 2/3 ENERGY data for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, a disease with no FDA-approved therapies. The 30 mg/kg group achieved statistically significant durable hemoglobin response and about three times more responders than placebo by 24 weeks.
Mean hemoglobin rose ≥1 g/dL by Week 1, nearly two-thirds met stringent hemoglobin targets by Week 24, fatigue and corticosteroid use improved, safety matched the existing profile, and the sBLA has FDA Priority Review.
Summary not available.
Johnson & Johnson (NYSE: JNJ) entered a definitive agreement to acquire Firefly Bio for $1 billion in cash, adding its proprietary Firelink™ degrader antibody conjugate (DAC) platform.
The deal aims to expand JNJ’s oncology pipeline targeting pan-KRAS and other hard-to-treat solid tumors and to strengthen its next-generation antibody engineering capabilities.